Real-World Seizure Reduction Outcomes with the NeuroPace RNS System to be Presented at the American Epilepsy Society 2019 Annual Meeting

Presentations to include safety and efficacy outcomes for patients treated with brain-responsive neuromodulation

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced that data from more than 30 studies of the RNS^® System, the first and only closed-loop system for refractory focal epilepsy, will be presented at the American Epilepsy Society (AES) 2019 Annual Meeting taking place December 6-10 in Baltimore. A key presentation will reveal new real-world seizure reduction outcomes achieved with the use of the company’s RNS System.

Additionally, a company-sponsored symposium titled “How Data Science is Transforming Epilepsy Treatment” will be held at 6:00 pm on Sunday, Dec. 8 in Key Ballroom 2. Presenters will include:

• Martha Morrell, MD, PhD, Clinical Professor of Neurology at Stanford University and Chief Medical Officer of NeuroPace.
• Dileep Nair, MD, Section Head of Adult Epilepsy at Cleveland Clinic.
• Sameer Sheth, MD, PhD, Associate Professor and Vice Chair of Clinical Research at Baylor College of Medicine.

Highlighted AES poster presentations on the RNS System include:

Saturday, December 7 12:00 p.m. – 2:00 p.m. Hall E:

• “Real-world experience with brain-responsive neurostimulation for focal onset seizures” by Babak Razavi, MD, PhD, Clinical Assistant Professor, Stanford Medicine.
• “Interim safety and effectiveness outcomes from a prospective post-approval trial of the RNS^® System” by Jerzy P. Szaflarski, MD, PhD, Director of University of Alabama Epilepsy Center.
• “Mood and quality of life in patients treated with brain-responsive neurostimulation: the value of earlier intervention” by David W. Loring, PhD, Director of Neuropsychology at Emory University.

Sunday, December 8 12:00 p.m. – 2:00 p.m. Hall E:

• “The effects of brain-responsive neurostimulation on sleep” by Leslie Ruoff, Technical Director and Sleep Research Consultant, San Francisco VA Medical Center.
• “Resective surgery and laser interstitial thermal therapy augmented with RNS System placement” by Ghazala Perven, MD, Assistant Professor, Department of Neurology and Neurotherapeutics at UT Southwestern Medical Center.

About the RNS^® System

The RNS System is the world’s first and only closed-loop brain-responsive neurostimulation system designed to prevent epileptic seizures at their source. The RNS System is composed of a neurostimulator, leads that are placed at the seizure foci, a remote monitor used by patients to upload their data, and a RNS Tablet and Patient Data Management System (PDMS) used by physicians. Physicians can view their patient’s electrographic data on a secure website and program the device to personalize therapy for each individual. Unlike anti-epileptic drugs or resective surgery, brain-responsive neuromodulation outcomes typically improve with time and do not cause the cognitive side effects that can be associated with those alternatives. The RNS System is now available at nearly all comprehensive epilepsy centers in the United States and is widely covered by private and government insurance.

The RNS System is an adjunctive therapy for adults with refractory, focal onset seizures with no more than 2 epileptogenic foci. See important safety information at https://neuropace.com/safety/

About NeuroPace

NeuroPace is the global leader in the emerging field of brain-computer interface technologies, which is projected to become a $1.2 billion market by 2024. We are dedicated to developing groundbreaking technology and advancing brain science to improve the quality of life for millions of individuals who suffer from neurological disorders. The company’s first product, the RNS System, is the only FDA-approved brain-responsive neurostimulator for the treatment of focal onset refractory epilepsy. In addition to treating epilepsy, brain-responsive neuromodulation holds the promise of treating other brain disorders that impact quality of life for millions of patients throughout the world.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191202005294/en/